ECSP044986A - Composicion farmaceutica que comprende lumiracoxib - Google Patents
Composicion farmaceutica que comprende lumiracoxibInfo
- Publication number
- ECSP044986A ECSP044986A EC2004004986A ECSP044986A ECSP044986A EC SP044986 A ECSP044986 A EC SP044986A EC 2004004986 A EC2004004986 A EC 2004004986A EC SP044986 A ECSP044986 A EC SP044986A EC SP044986 A ECSP044986 A EC SP044986A
- Authority
- EC
- Ecuador
- Prior art keywords
- tablets
- lumiracoxib
- pharmaceutical composition
- composition including
- fluoroanilino
- Prior art date
Links
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000994 lumiracoxib Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen aquí tabletas y métodos de tratamiento que comprenden la administración de dichas tabletas. Las tabletas son tabletas de liberación inmediata, que contienen aproximadamente 400 mg de ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético o una sal de él farmacéuticamente aceptable; en donde el ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético o una sal de él farmacéuticamente aceptable constituyen entre el 60 por ciento y el 70 por ciento en peso de la tableta. Los métodos comprenden administrar las tabletas de la invención a individuos que necesiten de la administración de dichas tabletas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31638901P | 2001-08-31 | 2001-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP044986A true ECSP044986A (es) | 2004-04-28 |
Family
ID=23228840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004004986A ECSP044986A (es) | 2001-08-31 | 2004-02-25 | Composicion farmaceutica que comprende lumiracoxib |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20030114527A1 (es) |
| EP (1) | EP1425005B1 (es) |
| JP (1) | JP4636796B2 (es) |
| KR (1) | KR100895551B1 (es) |
| CN (1) | CN100406008C (es) |
| AR (1) | AR036312A1 (es) |
| AT (1) | ATE324883T1 (es) |
| AU (1) | AU2002331094B2 (es) |
| BR (1) | BR0212155A (es) |
| CA (1) | CA2456604C (es) |
| CO (1) | CO5560554A2 (es) |
| CY (1) | CY1106137T1 (es) |
| DE (1) | DE60211183T2 (es) |
| DK (1) | DK1425005T3 (es) |
| EC (1) | ECSP044986A (es) |
| ES (1) | ES2263813T3 (es) |
| HU (1) | HUP0401429A2 (es) |
| IL (1) | IL160375A0 (es) |
| MX (1) | MXPA04001933A (es) |
| MY (1) | MY137516A (es) |
| NO (1) | NO20040860L (es) |
| NZ (1) | NZ531342A (es) |
| PE (1) | PE20030323A1 (es) |
| PL (1) | PL367464A1 (es) |
| PT (1) | PT1425005E (es) |
| RU (1) | RU2329801C2 (es) |
| SI (1) | SI1425005T1 (es) |
| WO (1) | WO2003020261A1 (es) |
| ZA (1) | ZA200400877B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR030630A1 (es) * | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| GB0201520D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Pharmaceutical uses |
| NZ534587A (en) * | 2002-03-07 | 2007-08-31 | Novartis Ag | Pharmaceutical composition containing 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid to treat a cyclooxygenase-2 dependent disorder |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20140093563A1 (en) * | 2011-06-13 | 2014-04-03 | Ranbaxy Laboratories Limited | Febuxostat compositions |
| US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| AU2015204763A1 (en) * | 2014-01-10 | 2016-07-21 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| EP3162362A1 (de) * | 2015-10-30 | 2017-05-03 | Dr. Falk Pharma Gmbh | Optimierte mesalazinhaltige hochdosistablette |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| EP4581160A1 (en) | 2023-08-24 | 2025-07-09 | 10X Genomics, Inc. | Methods, kits, and compositions for spatial detection of genetic variants |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0701449T3 (da) * | 1993-06-08 | 2003-11-10 | Novartis Ag | Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac |
| JPH11512754A (ja) * | 1996-05-17 | 1999-11-02 | メルク エンド カンパニー インコーポレーテッド | シクロオキシゲナーゼ―２媒介疾患の一日一回治療用組成物 |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| AR030630A1 (es) * | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
-
2002
- 2002-08-29 PE PE2002000832A patent/PE20030323A1/es not_active Application Discontinuation
- 2002-08-29 US US10/231,438 patent/US20030114527A1/en not_active Abandoned
- 2002-08-29 AR ARP020103257A patent/AR036312A1/es unknown
- 2002-08-30 EP EP02767455A patent/EP1425005B1/en not_active Expired - Lifetime
- 2002-08-30 KR KR1020047002925A patent/KR100895551B1/ko not_active Expired - Fee Related
- 2002-08-30 JP JP2003524569A patent/JP4636796B2/ja not_active Expired - Fee Related
- 2002-08-30 NZ NZ531342A patent/NZ531342A/en not_active IP Right Cessation
- 2002-08-30 MX MXPA04001933A patent/MXPA04001933A/es active IP Right Grant
- 2002-08-30 PT PT02767455T patent/PT1425005E/pt unknown
- 2002-08-30 AT AT02767455T patent/ATE324883T1/de active
- 2002-08-30 RU RU2004109920/15A patent/RU2329801C2/ru not_active IP Right Cessation
- 2002-08-30 DK DK02767455T patent/DK1425005T3/da active
- 2002-08-30 CN CNB02816895XA patent/CN100406008C/zh not_active Expired - Fee Related
- 2002-08-30 BR BR0212155-7A patent/BR0212155A/pt not_active IP Right Cessation
- 2002-08-30 HU HU0401429A patent/HUP0401429A2/hu unknown
- 2002-08-30 ES ES02767455T patent/ES2263813T3/es not_active Expired - Lifetime
- 2002-08-30 MY MYPI20023252A patent/MY137516A/en unknown
- 2002-08-30 DE DE60211183T patent/DE60211183T2/de not_active Expired - Lifetime
- 2002-08-30 WO PCT/EP2002/009701 patent/WO2003020261A1/en not_active Ceased
- 2002-08-30 SI SI200230367T patent/SI1425005T1/sl unknown
- 2002-08-30 CA CA2456604A patent/CA2456604C/en not_active Expired - Fee Related
- 2002-08-30 AU AU2002331094A patent/AU2002331094B2/en not_active Ceased
- 2002-08-30 IL IL16037502A patent/IL160375A0/xx unknown
- 2002-08-30 PL PL02367464A patent/PL367464A1/xx not_active Application Discontinuation
-
2004
- 2004-02-03 ZA ZA200400877A patent/ZA200400877B/en unknown
- 2004-02-25 EC EC2004004986A patent/ECSP044986A/es unknown
- 2004-02-25 CO CO04016658A patent/CO5560554A2/es not_active Application Discontinuation
- 2004-02-26 NO NO20040860A patent/NO20040860L/no not_active Application Discontinuation
-
2006
- 2006-08-03 CY CY20061101093T patent/CY1106137T1/el unknown
-
2007
- 2007-05-17 US US11/804,284 patent/US20070231382A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP044986A (es) | Composicion farmaceutica que comprende lumiracoxib | |
| ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| IT1245761B (it) | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. | |
| CO4750822A1 (es) | Formulaciones farmaceuticas tada para la administracion en el tracto gastrointestinal y procesos para elaborar las mismas | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| CO5280073A1 (es) | Composiciones | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| NO20055880L (no) | Memantin orale doseringsformer | |
| AR019053A1 (es) | Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen | |
| ES2168241T1 (es) | Preparacion farmaceutica que contiene tolperisona para administrar por via oral. | |
| ES2153906T3 (es) | Uso de incienso para el tratamiento de la enfermedad de alzheimer. | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| CO5190674A1 (es) | Tratamiento de desordenes neuroticos desordenes neuroticos | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
| AR087240A2 (es) | Composiciones farmaceuticas que tienen epinastina y pseudoefedrina | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca |